Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo

NCT04927975 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04927975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04927975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2021
Completion date
August 29, 2023
Enrollment
185 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo